Table 1.

miR signatures of hallmark capabilities of cancer

(A) miRs differentially expressed more than twofold relative to the previous stage with a P-value of <0.05, Student's t-test. (B) miRs differentially regulated in metastases. Many miRs are altered in metastases, the majority of which are similarly altered in met-like primary tumors. The “metastasis-specific signature” miRs are only altered in metastases. (C) Angiogenesis-inhibited signature miRs are those differentially altered in normal versus sunitinib-treated primary tumors by >1.3-fold, with a P-value of <0.05.